Literature DB >> 10501630

Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines.

S P Raychaudhuri1, E M Farber, S K Raychaudhuri.   

Abstract

Peptide T is an octapeptide from the V2 region of HIV-1 gp120. It has been shown to resolve psoriatic lesions--an inflammatory skin disease. The mechanisms of anti-inflammatory actions of peptide T are not well understood. Th1 cytokines such as IL-2, and IFN-gamma are upregulated in psoriasis. These cytokines play a key role in the inflammatory and proliferative processes of psoriasis. The effects of peptide T on Th1 and Th2 cytokines were studied in order to elucidate the mechanisms of antiinflammatory actions of peptide T. It was observed that peptide T at 10(-8) M induces IL-10 production by the human Th2 cell line and PBMC (P < 0.05, ANOVA). Also peptide T at 10(-9) M concentration significantly inhibited IFN-gamma production by PBMC (P < 0.001, ANOVA). Anti IL-10 antibody inhibited the anti-IFN-gamma effect of peptide T (P < 0.05, t-test). Our study shows that peptide T induces IL-10 production and inhibits IFN-gamma production. IL-10 is a potent anti-inflammatory cytokine. It inhibits IL-2 and IFN-gamma production from the T cells and downregulates the expression of TNF-alpha in the antigen presenting cells. Recently, IL-10 has been shown to resolve psoriatic lesions. The effects of peptide T on IL-10 and IFN-gamma production provides a plausible explanation for its clinical efficacy in psoriasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501630     DOI: 10.1016/s0192-0561(99)00041-7

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  2 in total

1.  Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats.

Authors:  I Sáez-Torres; C Espejo; J J Pérez; N Acarín; X Montalban; E M Martínez-Cáceres
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

2.  Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment.

Authors:  Karl Goodkin; Benedetto Vitiello; William D Lyman; Deshratn Asthana; J Hampton Atkinson; Peter N R Heseltine; Rebeca Molina; Wenli Zheng; Imad Khamis; Frances L Wilkie; Paul Shapshak
Journal:  J Neurovirol       Date:  2006-06       Impact factor: 2.643

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.